These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 16338624)
1. Interleukin 12 is associated with reduced relapse without increased incidence of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Reddy V; Winer AG; Eksioglu E; Meier-Kriesche HU; Schold JD; Wingard JR Biol Blood Marrow Transplant; 2005 Dec; 11(12):1014-21. PubMed ID: 16338624 [TBL] [Abstract][Full Text] [Related]
2. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation]. Lin Q; Dong M; Wang QM; Wen JY; Wu XY Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772 [TBL] [Abstract][Full Text] [Related]
3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
4. Increased levels of tumor necrosis factor alpha are associated with an increased risk of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Reddy V; Meier-Kriesche HU; Greene S; Schold JD; Wingard JR Biol Blood Marrow Transplant; 2005 Sep; 11(9):698-705. PubMed ID: 16125640 [TBL] [Abstract][Full Text] [Related]
5. Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients. Shaiegan M; Iravani M; Babaee GR; Ghavamzadeh A Transpl Immunol; 2006 Jan; 15(3):223-7. PubMed ID: 16431290 [TBL] [Abstract][Full Text] [Related]
6. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801 [TBL] [Abstract][Full Text] [Related]
7. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia. Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296 [TBL] [Abstract][Full Text] [Related]
8. Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia. Nordlander A; Mattsson J; Ringdén O; Leblanc K; Gustafsson B; Ljungman P; Svenberg P; Svennilson J; Remberger M Biol Blood Marrow Transplant; 2004 Mar; 10(3):195-203. PubMed ID: 14993885 [TBL] [Abstract][Full Text] [Related]
9. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia. Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755 [TBL] [Abstract][Full Text] [Related]
10. Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes. Uberti JP; Ayash L; Braun T; Reynolds C; Silver S; Ratanatharathorn V Bone Marrow Transplant; 2004 Sep; 34(5):425-31. PubMed ID: 15273705 [TBL] [Abstract][Full Text] [Related]
11. Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation. Mahindra A; Bolwell B; Sobecks R; Rybicki L; Pohlman B; Dean R; Andresen S; Sweetenham J; Kalaycio M; Copelan E Br J Haematol; 2009 Aug; 146(3):310-6. PubMed ID: 19508292 [TBL] [Abstract][Full Text] [Related]
12. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Kröger N; Perez-Simon JA; Myint H; Klingemann H; Shimoni A; Nagler A; Martino R; Alegre A; Tomas JF; Schwerdtfeger R; Kiehl M; Fauser A; Sayer HG; Leon A; Beyer J; Zabelina T; Ayuk F; San Miguel JF; Brand R; Zander AR Biol Blood Marrow Transplant; 2004 Oct; 10(10):698-708. PubMed ID: 15389436 [TBL] [Abstract][Full Text] [Related]
13. Circulating IL-17 levels during the peri-transplant period as a predictor for early leukemia relapse after myeloablative allogeneic stem cell transplantation. Cho BS; Lim JY; Yahng SA; Lee SE; Eom KS; Kim YJ; Chung NG; Jeong DC; Lee S; Kim HJ; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Min CK Ann Hematol; 2012 Mar; 91(3):439-48. PubMed ID: 21894475 [TBL] [Abstract][Full Text] [Related]
14. Clinical impact of graft-versus-host disease against leukemias not in remission at the time of allogeneic hematopoietic stem cell transplantation from related donors. The Japan Society for Hematopoietic Cell Transplantation Working Party. Kataoka I; Kami M; Takahashi S; Kodera Y; Miyawaki S; Hirabayashi N; Okamoto S; Matsumoto N; Miyazaki Y; Morishita Y; Asai O; Maruta A; Yoshida T; Imamura M; Hamajima N; Matsuo K; Harada M; Mineishi S; Bone Marrow Transplant; 2004 Oct; 34(8):711-9. PubMed ID: 15361916 [TBL] [Abstract][Full Text] [Related]
15. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia]. Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125 [TBL] [Abstract][Full Text] [Related]
16. Risk assessment and outcome of chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell transplantation in pediatric patients. Diaz MA; Vicent MG; Gonzalez ME; Verdeguer A; de la Rubia J; Bargay J; de Arriba F; Diez JL; Caballero D; Madero L; Brunet S; Bone Marrow Transplant; 2004 Sep; 34(5):433-8. PubMed ID: 15273704 [TBL] [Abstract][Full Text] [Related]
17. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686 [TBL] [Abstract][Full Text] [Related]
18. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation. Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173 [TBL] [Abstract][Full Text] [Related]
19. Human herpes virus 6 plasma DNA positivity after hematopoietic stem cell transplantation in children: an important risk factor for clinical outcome. de Pagter PJ; Schuurman R; Visscher H; de Vos M; Bierings M; van Loon AM; Uiterwaal CS; van Baarle D; Sanders EA; Boelens J Biol Blood Marrow Transplant; 2008 Jul; 14(7):831-9. PubMed ID: 18541204 [TBL] [Abstract][Full Text] [Related]
20. Chronic kidney dysfunction in patients alive without relapse 2 years after allogeneic hematopoietic stem cell transplantation. Abboud I; Porcher R; Robin M; de Latour RP; Glotz D; Socié G; Peraldi MN Biol Blood Marrow Transplant; 2009 Oct; 15(10):1251-7. PubMed ID: 19747632 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]